In the dense forests of the Democratic Republic of Congo, a rare and deadly strain of Ebola has infected more than 1,100 people and claimed nearly 250 lives, igniting an urgent global race to develop a vaccine that barely existed weeks ago. This is only the third outbreak of Bundibugyo Ebola in recorded history, but its emergence has catalyzed an unprecedented mobilization: three major non-profit organizations announced coordinated vaccine development efforts on Monday alone, each betting on different scientific approaches to contain a virus for which there are no approved treatments or vaccines.
The scale of the crisis would be difficult to overstate. While this marks the 17th Ebola outbreak in the DRC, the Bundibugyo strain is uniquely challenging because years of limited commercial interest have left the scientific arsenal nearly bare. The virus devastates communities already fractured by hunger, malaria, and conflict, making both vaccine trials and community trust delicate undertakings. Yet researchers have found reason for optimism in an unlikely place: a vaccine that has sat dormant for more than a decade, shelved precisely because pharmaceutical firms saw little profit in preparing for a disease that rarely struck.
The World Health Organization identified the rVSV platform—a single-dose vaccine approach—as the most promising candidate. Thomas Geisbert, a virologist at the University of Texas Medical Branch, led development of both this Bundibugyo candidate and the only licensed Ebola vaccine available today, which targets the more common Zaire strain. Geisbert's 2013 research demonstrated remarkably strong protection against Bundibugyo in primates, yet the vaccine languished in obscurity for a decade. Now, the International AIDS Vaccine Initiative has signed a deal with Geisbert's university to fast-track the rVSV candidate toward clinical trials—a process the WHO estimates will take seven to nine months.
Parallel tracks are racing alongside. The Coalition for Epidemic Preparedness Innovations committed $50 million to accelerate three vaccine candidates, including $3.2 million specifically for the rVSV jab. A second candidate, built on the University of Oxford's ChAdOx1 platform (the same technology underlying AstraZeneca's COVID vaccine), could reach clinical trials within two to three months and will be manufactured by India's Serum Institute. Moderna is also in the race, with CEPI funding its mRNA-based candidate—the same messenger RNA technology that powered its COVID vaccine.
The investment signals unprecedented confidence, yet funding alone will not guarantee success. The Gavi vaccine alliance pledged up to $50 million more, with its CEO Sania Nishtar stressing that "we need to act now to ensure that, once one or more vaccine candidates are ready, manufacturers are in a position to start producing doses at scale." That $50 million, according to IAVI president Mark Feinberg, could fund production of roughly 500,000 doses—enough to launch a meaningful trial.
But even manufactured doses face daunting barriers. The vast, remote terrain of the DRC's outbreak epicenter presents logistical nightmares. Gaining the trust of communities ravaged by crisis and skepticism toward outside intervention remains crucial. And once trials begin, there is no certainty they will prove the vaccine effective. As CEPI CEO Richard Hatchett cautioned, "we have to treat them as investigational products." What began as an abandoned scientific shelf has become a race against both time and the unknowable, with multiple nations and organizations refusing to wait.